Researchers at University of California, Irvine have engineered lectin-based therapeutic proteins with a Velcro-like strong and highly specific binding to tumor-associated carbohydrate antigens. This approach discriminates between cancerous and healthy cells without protein targeting, offering pan-cancer immunotherapy potential. Separately, Avenzo Therapeutics initiated a Phase 1/2 clinical trial of AVZO-103, a bispecific antibody-drug conjugate targeting Nectin4 and TROP2, with hopes for a best-in-class ovarian cancer treatment leveraging induced mesenchymal stem cells as delivery vehicles. These innovations represent promising therapeutic frontiers in oncology.